NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on MRD-based protocol
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F23%3A10448807" target="_blank" >RIV/00216208:11130/23:10448807 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064203:_____/23:10448807
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=S0MZUQyBdb" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=S0MZUQyBdb</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2022017003" target="_blank" >10.1182/blood.2022017003</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on MRD-based protocol
Popis výsledku v původním jazyce
We compared minimal residual disease (MRD) levels evaluated by routinely used real-time quantitative PCR (qPCR) patient-specific assays and by next generation sequencing (NGS) approach in 780 immunoglobulin/T-cell receptor (IG/TR) markers in 432 children with B-cell precursor acute lymphoblastic leukemia (ALL) treated on the AIEOP-BFM ALL 2009 protocol. Our aim was to compare the MRD-based risk stratification at the end of induction (EOI). The results were concordant in 639/780 (81.9%) of these markers, 37/780 (4.7%) markers were detected only by NGS. In 104/780 (13.3%) markers positive only by qPCR, a large fraction (23/104; 22.1%) was detected also by NGS, however, due to the presence of identical IG/TR rearrangements in unrelated samples, we classified those as nonspecific/falsely-positive. Risk group stratification based on the MRD results by qPCR and NGS at EOI was concordant in 76% of the patients, 19% of the patients would be assigned to a lower-risk group by NGS, largely due to the elimination of false-positive qPCR results, and 5% of patients would be assigned to a higher risk group by NGS. NGS MRD is highly concordant with qPCR while providing more specific results and can be an alternative in the frontline MRD evaluation in forthcoming MRD-based protocols.
Název v anglickém jazyce
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on MRD-based protocol
Popis výsledku anglicky
We compared minimal residual disease (MRD) levels evaluated by routinely used real-time quantitative PCR (qPCR) patient-specific assays and by next generation sequencing (NGS) approach in 780 immunoglobulin/T-cell receptor (IG/TR) markers in 432 children with B-cell precursor acute lymphoblastic leukemia (ALL) treated on the AIEOP-BFM ALL 2009 protocol. Our aim was to compare the MRD-based risk stratification at the end of induction (EOI). The results were concordant in 639/780 (81.9%) of these markers, 37/780 (4.7%) markers were detected only by NGS. In 104/780 (13.3%) markers positive only by qPCR, a large fraction (23/104; 22.1%) was detected also by NGS, however, due to the presence of identical IG/TR rearrangements in unrelated samples, we classified those as nonspecific/falsely-positive. Risk group stratification based on the MRD results by qPCR and NGS at EOI was concordant in 76% of the patients, 19% of the patients would be assigned to a lower-risk group by NGS, largely due to the elimination of false-positive qPCR results, and 5% of patients would be assigned to a higher risk group by NGS. NGS MRD is highly concordant with qPCR while providing more specific results and can be an alternative in the frontline MRD evaluation in forthcoming MRD-based protocols.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
<a href="/cs/project/NU20-03-00284" target="_blank" >NU20-03-00284: Imunomonitoring pomocí přestaveb genů pro receptory antigenů ve vztahu k léčebné odpovědi u nádorových onemocnění</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Blood
ISSN
0006-4971
e-ISSN
1528-0020
Svazek periodika
141
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
5
Strana od-do
529-533
Kód UT WoS článku
000935173600001
EID výsledku v databázi Scopus
2-s2.0-85145607891